Fig. 9.
Fig. 9. Expression of TRAIL receptors and intracellular apoptosis regulator proteins in myeloma cells treated with the NF-κB inhibitor SN50. / Immunoblot analysis for TRAIL receptors (DR4, DR5, DcR1, DcR2), procaspase-8, procaspase-10, procaspase-3, FLIP, cIAP1, cIAP2, XIAP, survivin, Bcl2, and Bcl-xL in TRAIL-sensitive (MM.1S) and moderately resistant (ARH-77) cells treated with and without the NF-κB inhibitor SN50 (30 μg/mL) for 6 hours. Levels of tubulin are shown for confirmation of equal protein loading.

Expression of TRAIL receptors and intracellular apoptosis regulator proteins in myeloma cells treated with the NF-κB inhibitor SN50.

Immunoblot analysis for TRAIL receptors (DR4, DR5, DcR1, DcR2), procaspase-8, procaspase-10, procaspase-3, FLIP, cIAP1, cIAP2, XIAP, survivin, Bcl2, and Bcl-xL in TRAIL-sensitive (MM.1S) and moderately resistant (ARH-77) cells treated with and without the NF-κB inhibitor SN50 (30 μg/mL) for 6 hours. Levels of tubulin are shown for confirmation of equal protein loading.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal